Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET

Company Participants

Andrew McKibben - Vice President, Investor Relations
Chris Peetz - Chief Executive Officer
Peter Radovich - President & Chief Operating Officer
Joanne Quan - Chief Medical Officer
Eric Bjerkholt - Chief Financial Officer

Conference Call Participants

Gavin Clark-Gartner - Evercore ISI.
Jessica Fye - JP Morgan
Dae Gon Ha - Stifel
Brian Skorney - Baird
David Lebowitz - Citi
Thomas Yip - H.C. Wainwright

Operator

Hello everyone, and welcome to the Mirum Pharmaceuticals' Third Quarter 2024 Financial Results and Business Update. My name is Seb [ph] and I'll be the operator for your call today. [Operator Instructions].

I will now hand you over to Andrew McKibben, Vice President of Investor Relations and Finance. Please go ahead.

Andrew McKibben

Thanks Seb, and good morning everyone. I'd like to welcome you to Mirum Pharmaceuticals third quarter 2024 conference call. I'm joined today by our CEO, Chris Peetz, our President and Chief Operating Officer, Peter Radovich, our Chief Medical Officer, Joanne Quan, and Eric Bjerkholt, our Chief Financial Officer.

Earlier today, Mirum issued a news release announcing the company's results for the third quarter 2024. Copies of this news release and SEC filings can be found in the investors section of our website. Before we start, I'd like to remind you that during the course of this conference call, we will be making certain forward-looking statements based on management's current expectations, including statements regarding Mirum's programs and market opportunities for its approved medicines and product candidates.

These statements represent our judgment as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the results discussed. We are under no duty to update these statements. Please refer to the risk factors in